Searched for
CANCER DRUGS PIPELINE
$10. 6 billion deal: GSK to buy US cancer specialist NuvalentBritish pharmaceutical giant GSK has announced a massive $10.6 billion deal to acquire Nuvalent. This Boston-based company specializes in c...- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Sakar Healthcare partners with Zydus Lifesciences for GCC MarketsSakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks ...
- From oncology to obesity, Pfizer bets big on India for its next growth wavePfizer is prioritizing India for future growth. The company plans to launch new medicines here soon after their global release. Pfizer aims...
- Zydus Lifesciences shares jump 6% on buyback buzz; co announces $166 mn Assertio acquisitionZydus Lifesciences shares witnessed a spike on Thursday after the company said its board will meet on May 19 to consider a share buyback. T...
- Zydus Lifesciences close to buying US oncology drug maker for $100 to 150 million: SourcesIndian drug maker Zydus Lifesciences is close to acquiring a US company. The deal is expected to be between $100 to $150 million. This acqu...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- US market today: Pfizer posts strong first-quarter, sees boost from recent legal winsPfizer reported higher-than-expected sales and profit on Tuesday and said a patent extension for its Vyndamax heart drug and a recent favor...
- Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: ReportBiocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...
- Amazon launches AI research tool to speed early-stage drug discoveryAmazon Web Services has launched Amazon Bio Discovery, an AI tool to accelerate drug discovery. Scientists can now generate and evaluate po...
- Market bets on Aurobindo as Europe, US sales show uptickAurobindo Pharma stock is performing well. Sales in Europe are improving. New products are launching in the US. The company is also develop...
- Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipelineGilead is making headlines with its planned acquisition of Tubulis GmbH, a Germany-based company, for a maximum of five billion dollars. Th...
- Merck braces for Keytruda patent loss with $6.7 billion Terns betMerck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...
- Novartis to buy experimental breast cancer drug in up to $3 billion dealSwiss drugmaker Novartis is set to acquire a promising breast cancer drug candidate from US biotech firm Synnovation Therapeutics. The deal...
- Merck KGaA bets on cancer drugs to revitalise German firmMerck KGaA is betting on its oncology pipeline to revitalise the German drugmaker as it sees falling sales from its best-selling medicine, ...
- Good cancer drug data helps AstraZeneca in Pfizer fightBritain's second-biggest drugmaker has rejected a $106 billion approach from its US rival Pfizer, arguing that it has a bright future.
- Major pharma-deals: How anti-cancer drugs are reshaping the pharmaceutical industryNew and considerable optimism over cancer drugs will drive deal-making in pharma over the decade, with companies weak in this segment tryin...
Load More
